Trends of EBV Serology in Screening of Nasopharyngeal Cancer in a Multiethnic Healthy Singaporean Cohort
- 22 July 2026
- journal article
- research article
- Published by Wiley in Head & Neck
Abstract
Background: Epstein–Barr virus–positive nasopharyngeal carcinoma (EBV‐NPC) is highly prevalent in Asia. EBV IgA serologies (targeting viral capsid antigen [VCA] and early antigen [EA]) are commonly used for NPC screening in Singapore. However, the predictive value of longitudinal serologic trends in real‐world screening remains unclear. This study evaluated EBV IgA serologic patterns and their relationship with NPC development. Methods: We conducted a retrospective cohort study of 1977 asymptomatic individuals screened for NPC between 2008 and 2021 at a tertiary medical center in Singapore. Patients were predominantly Chinese (95%) and aged 12–90 years. Data on EBV IgA serologies (EA‐IgA and VCA‐IgA), plasma EBV DNA, nasoendoscopy, biopsies, and MRI findings were collected. Primary outcomes included EBV serologic trends (stratified into positive for only one serology type, non‐fluctuating positivity, fluctuating positivity, seroconversion or seroreversion) and incidence of NPC during follow‐up. Results: Of the 1977 patients, 62% tested positive for either EA‐IgA or VCA‐IgA. 7.2% showed stable positive titers, 5% had fluctuating titers, 2.4% seroconverted, and 23.5% seroreverted. Six patients (0.3%) developed NPC; all were Chinese, with a mean age of 50. Three had Stage I, one had Stage III, and two had Stage IV disease. Their serologic trajectories varied with no consistent pattern observed. Elevated EBV EA‐IgA (2/6) or VCA‐IgA (2/6) titers were observed 1–2 years before diagnosis. Conclusion: No consistent EBV serologic pattern preceded NPC diagnosis in this cohort. The low NPC detection rate of 0.3% suggests limited screening utility of EBV serologies in a heterogeneous, intermediate‐risk population.Keywords
This publication has 14 references indexed in Scilit:
- Recommendations for Epstein-Barr virus–based screening for nasopharyngeal cancer in high- and intermediate-risk regionsJNCI: Journal of the National Cancer Institute, 2023
- Provider-perceived barriers to patient adherence to colorectal cancer screeningPreventive Medicine Reports, 2021
- Cost-Effectiveness of Nasopharyngeal Carcinoma Screening With Epstein-Barr Virus Polymerase Chain Reaction or Serology in High-Incidence Populations WorldwideJNCI: Journal of the National Cancer Institute, 2020
- A comparison of EBV serology and serum cell‐free DNA as screening tools for nasopharyngeal cancer: Results of the Singapore NPC screening cohortInternational Journal of Cancer, 2019
- Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern ChinaAnnals of Oncology, 2019
- Elevated antibodies against Epstein-Barr virus among individuals predicted to carry nasopharyngeal carcinoma susceptibility variantsJournal of General Virology, 2018
- Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal CancerNew England Journal of Medicine, 2017
- Epstein-Barr Virus Antibodies and the Risk of Associated Malignancies: Review of the LiteratureAmerican Journal of Epidemiology, 2014
- Two Epstein-Barr Virus-Related Serologic Antibody Tests in Nasopharyngeal Carcinoma Screening: Results From the Initial Phase of a Cluster Randomized Controlled Trial in Southern ChinaAmerican Journal of Epidemiology, 2012
- Sustained elevation of Epstein–Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinomaBritish Journal of Cancer, 2007